Corporate Presentation

Obesity Petrelintide Results from Part 2 of the trial, exploring higher doses of petrelintide over 16 weeks, are expected in H1 2024 ZEAL& ZEALAND PHARMA ÅÅÅ >>> We are investigating significantly higher doses of petrelintide... ...over a longer duration of 16 weeks... ... using a dose-escalation scheme... ...in 48 people who are overweight or have obesity The next step in the development of petrelintide will be a comprehensive Phase 2 program to be initiated in H2 2024 Source: ClinicalTrials.gov (NCT05613387), accessed November 2023. 18

View entire presentation